Dallas, TX - June 28, 2016 – Puration, Inc. (PURA) today announced a Cannabidiol (CBD) Crystal Extract. CBD’s therapeutic potential was recognized and acknowledged last year in a National Institute on Drug Abuse Senate Caucus on International Narcotics Control. Puration began one year ago to develop the commercial application of a U.S. Patented cannabis extraction process. Various extracts derived from the patented process have been trialed with positive results in the treatment of illnesses including veterans suffering from PTSD, children with autism, various types of cancer, patients with a variety of neurological disorders, pain management, auto-immune disorders and seizures due to Epilepsy.
The CBD Crystal Isolate Extract announced today is the latest benchmark in the Company’s ongoing campaign to develop a line of commercial applications from a variety of cannabis extracts. The Company has already begun testing of the Crystal Isolate. Independent research suggests a water soluble CBD product may demonstrate better bioavailability than an oil delivered CBD product.
Learn more about Puration, Inc. and keep up to date on the rapid changes anticipated throughout 2016 on the Company's website: http://www.purationinc.com/.